Prandial glucose regulators (Glinides)

An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.

The oral antidiabetic drug repaglinide controls blood glucose levels as effectively as insulin in patients with newly diagnosed cystic-fibrosis-related diabetes, study findings indicate.